Assistant Professor of Radiation and Cellular Oncology, University of Chicago Medicine
Radiation Oncology
Dr. Michael Spiotto, MD
|
|
Give Review
Michael Spiotto is an expert in the field of Radiation Oncology. He researched medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine has a rank of 10 in research and a 19 in primary care Michael Spiotto is a published doctor as well. He has 28 publications published. The latest was: Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer. He is registered with Medicare and accepts Medicare payments.
Publications
- Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer.
- Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers.
- Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer.
- Disparities in Treatment of Patients with Inoperable Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis.
- The Effect of Radiotherapy Dose on Survival in Stage III Non-Small-Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy.
- Bioluminescent Imaging of HPV-Positive Oral Tumor Growth and Its Response to Image-Guided Radiotherapy.
- Effect of Postradiotherapy Neck Dissection on Nonregional Disease Sites.
- Race and competing mortality in advanced head and neck cancer.
- Racial parities in outcomes after radiotherapy for head and neck cancer.
- Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and ne...
- Lymph node density - Prognostic value in head and neck cancer.
- Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.
- Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.
- Genetic changes occurring in established tumors rapidly stimulate new antibody responses.
- Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.
- Bystander elimination of antigen loss variants in established tumors.
- Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.
- Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombination.
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
- Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients.
- Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
- Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
- Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy.
- Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth.
- Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
- Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or without Simultaneous Integrated Boost during Concurrent Chemoradiation for Locally...
- Animal Models to Study the Mutational Landscape for Oral Cavity and Oropharyngeal Cancers.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Education
-
Stanford University -
Memorial Sloan-Kettering Cancer Center -
University of Chicago Pritzker School of Medicine
Hospital
-
University of Chicago Medical Center -
University of Illinois Hospital & Health Sciences System -
Jesse Brown Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1386831030 | |
| NPPES Provider LastName | SPIOTTO | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 606371426 | |
| NPPES Provider State | IL | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 11.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1386831030 |
| Last Name Of The Provider | SPIOTTO |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Jonathan B. Strauss, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maryanne H. Marymont, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Sher, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ralph R. Weichselbaum, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Sonal U. Mayekar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley V. Hoover, MD |
|
|
Dr. Gregory E. Kauffmann, MD |
|
|
Dr. Amanda J. Walker, MD |
|
|
Dr. Neilayan Neilayan, MD |